Concept Life Sciences is a knowledge-based, science-led business providing a wide range of innovative and integrated solutions to clients in the pharmaceutical, biotechnology, food, agrochemical, petrochemical, chemical, cosmetics and consumer products sectors.
Concept was formed in 2014 following the merger of SAL, Agenda1 Analytical Services, Peakdale Molecular, CXR Biosciences and REC. Since then we have expanded through a mix of organic growth and targeted acquisition, most recently Aquila Biomedical in 2018. Today we are home to more than 250 employees, working from seven laboratories across the UK.
We have brought together teams of highly trained scientists, excellent laboratory facilities and an in-depth understanding of our core markets, and created a business that is greater than the sum of its parts.
Our teams share a common focus on problem solving, quality, collaboration, communication and flexibility and deliver a comprehensive platform of services in the Pharmaceutical, Crops & Chemicals and Food sectors.
In January 2018 Concept was acquired by Spectris plc, a leading supplier of productivity-enhancing instrumentation and controls. The company’s products and technologies help customers to improve product quality and performance, improve core manufacturing processes, reduce downtime and wastage and reduce time to market.
The acquisition has underpinned Concept Life Sciences’ international growth and expansion into new markets and provides customers with access to a broader range of services due to synergies with other Spectris operating companies. This includes, but is not limited to, molecular testing and analysis expertise with Malvern Panalytical and excellence in contamination monitoring with Particle Measuring Systems (PMS).
To find out more about Spectris and our shared company values visit, www.spectris.com